2023-510548-19-00
CTIS ↗
Namodenoson, Matching placebo for namodenoson
Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis
biotech · Plaque Psoriasis · Rheumatoid Arthritis · CANF
Can Fite Biopharma
Can-Fite BioPharma
Can Fite Biopharma trial registry — 24 ClinicalTrials.gov studies with program phase, status, and indication context.
10 Bareket Street, פ"ת, IL, RAMAT GAN, L3, USA HQ
9 Employees
Public company Type
CANF · NYSE Ticker
Company details
- Status
- Public
- HQ
- 10 Bareket Street, פ"ת, IL, RAMAT GAN, L3, USA
- Employees
- 9
- Programs
- 20
- Drugs
- 4
- Patents
- 23
Can Fite Biopharma clinical trials
Registry index of 24 ClinicalTrials.gov studies linked to Can Fite Biopharma programs — each row shows trial ID, program name, phase, status, and indication.
Can Fite Biopharma trial registry — 24 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Can Fite Biopharma.
-
Piclidenoson — Phase 2
Clinical update -
Namodenoson, Matching placebo for namodenoson — Phase 2
Clinical update -
Matching Placebo for Piclidenoson, Piclidenoson — Phase 3
Clinical update -
Namodenoson — Phase 2
Clinical update -
CF102 — Phase 2
Clinical update -
CF101 — Phase 3
Clinical update -
CF101 — Phase 3
Clinical update -
CF101 1 mg — Phase 3
Clinical update